Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telo GenomicsTDSGF Return-on-Tangible-Asset is -287.07% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Telo Genomics ranks worse than 95.77% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Telo Genomics's annualizedNet Income for the quarter that ended in Mar. 2026 was $-1.63 Mil. Telo Genomics's average total tangible assets for the quarter that ended in Mar. 2026 was $0.57 Mil. Therefore, Telo Genomics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -287.07%.
The historical rank and industry rank for Telo Genomics's Return-on-Tangible-Asset or its related term are showing as below:
TDSGF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -533.82 Med: -158 Max: -13.12
Current: -261.77
During the past 13 years, Telo Genomics's highest Return-on-Tangible-Asset was -13.12%. The lowest was -533.82%. And the median was -158.00%.
TDSGF's Return-on-Tangible-Asset is ranked worse than 95.77% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs TDSGF: -261.77
Telo Genomics (OTCPK:TDSGF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Telo Genomics Return-on-Tangible-Asset Related Terms
Telo Genomics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Telo Genomics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TDSGF vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Telo Genomics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telo Genomics Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Telo Genomics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -287.07% mean?
Telo Genomics (TDSGF) has a Return-on-Tangible-Asset of -287.07% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Telo Genomics and its competitors. According to the industry distribution chart, Telo Genomics ranks #204 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 95.8%.
Is Telo Genomics' Return-on-Tangible-Asset too high?
Telo Genomics' current Return-on-Tangible-Asset is -287.07%. Based on the distribution chart, Telo Genomics ranks #204 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Telo Genomics' Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Telo Genomics ranks #204 out of 213 companies for Return-on-Tangible-Asset. This places Telo Genomics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Telo Genomics and its competitors. Telo Genomics's current Return-on-Tangible-Asset is -287.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current Return-on-Tangible-Asset of -287.07%. The current Return-on-Tangible-Asset is -287.07%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current Return-on-Tangible-Asset is -287.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TDSGF has been successfully added to your 
